Guess who's back? Back again…

The FDA just gave Moderna the all-clear to unleash its latest Covid-19 vaccine, mNEXSPIKE, on the public… that is, provided you’re either collecting Social Security or just one Taco Tuesday away from a hospital visit. Simply put, the new approval is laser-focused: adults 65+ and those 12 to 64 with at least one risk factor (think: asthma, diabetes, “my doctor says I need to chill out but I won’t”). Healthy kids and pregnant women, congrats you dodged a bullet… this jab isn’t for you. 

(Source: Giphy) 

Why? Because the CDC… under the watchful, slightly conspiratorial eye of Robert F. Kennedy Jr., is no longer recommending Covid shots for that demographic. Translation: Make it modern medicine, but “members only”. However, with that said, buried in Moderna’s press release is the claim that Covid-19 is still killing more than 47,000 Americans a year. CEO Stéphane Bancel called the new approval “an important tool” for the at-risk. But what he didn’t say is that this is the first Covid vax greenlit since the FDA went full hall monitor and made Big Pharma jump through extra hoops for anything targeting healthy adults. Which only leads me to this question: Did Purdue Pharma’s all-star approval machine Curtis Wright sneak back through the revolving door? Asking for a friend…

Alright, alright… all sarcasm aside. mNEXSPIKE is a lower dose (a.k.a. one-fifth the size of OG Spikevax). Meaning, according to the experts, this is not a mandatory upgrade… just an alternative that will be out for the 2025-26 virus season. Translation: It’ll be out just in time for whichever plandemic “The Swamp” has waiting for us next. 

(Source: Axios) 

As for the clinical trials, the receipts are as follows: Moderna ran the numbers on 11,400 people and… wouldn’t you know it… mNEXSPIKE supposedly outperformed the original by 9.3% for everyone 12+, and by a beefier 13.5% for the 65+ crowd. In terms of side effects, we’re looking at the usual: arm pain, fatigue, mild regret about trusting medical science, etc. Local reactions (redness, swelling) were a touch lower with the new stuff, but the flu-like symptoms are here to stay. Take two Tylenol and try not to Google anything for 48 hours.

Additionally, this shot was also tested as an “active comparator”, meaning they stacked it up against the old vaccine, not a saline placebo. This is actually smart. Why? Because the new Trump-era FDA wants all future shots to face off against a real inert placebo. Plus, science is funnier when there's no B.S. gaslighting opportunities attached to “results”.

(Source: Giphy) 

For investors though, it doesn’t take a genius to expect some big swingin’ green candles today. The OG vax stocks have been waiting for a catalyst to get them back into the headlines since social distancing went the way of the Dinosaurs. And for Moderna, this is exactly that. Now obviously, don’t hold me to that… anything can happen when it comes to price action today. But when you’re single-handedly serving the health of old, immunocompromised boomers, who have medical charts longer than a CVS receipt (and likely make up the large majority of Wall Street)... this is bullish news. 

With that said though, don’t be dumb. Make sure you do your due diligence before YOLOing a second mortgage into Moderna. For now, keep your eyes on this story and place your bets accordingly. Until next time, friends… 

P.S. $27K to feel like a big shot?

Personal story: When I started investing, the only “edge” I had was the fantasy of selling a kidney for Bloomberg Terminal money. Seriously, that’s what Wall Street expects you to cough up… twenty-seven grand for the privilege of watching news break a few minutes before the rest of the peasants.

Which makes sense, especially considering that by the time retail traders even sniff that info, the real money’s already been made. The suits have already vacuumed up the opportunity while everyone else is left buying tops, bag-holding, and rage-posting on Reddit. I learned that the hard way… but after I finally wised up about what the Bloomberg Terminal actually is. Spoiler: it’s finance’s version of slapping a Chanel label on a bottle of Febreze. It’s not about the data. It’s about knowing where to get it before some hedge fund manager with a cocaine addiction and racked up child support front-runs your trade.

This is exactly why Stocks.News exists. Seriously. The days of mortgaging your future or harvesting organs just to keep up with the Wall Street greed bags are over. Now it’s time to get the same real-time, unfiltered news flow the pros get… without the “bend over and take it” annual fee. All the ammo, none of the institutional gatekeeping.

Translation: It’s time to dump the $20k+ price tag with yesterday’s lunch. You want actionable news before its ancient history? Stocks.News premium costs less than whatever sad desk salad corporate America is eating right now. Meaning here’s where you stop getting played… and start winning. Click here to join Stocks.News premium and finally clinch your seat at the big kids’ table. 

Stocks.News holds positions in Moderna as mentioned in the article.